Charles River Associates announces six VP promotions
Charles River Associates today announced the promotions of six new vice presidents. Sean Sheridan in CRA’s Intellectual Property Practice, Eddie Li, Erika...
CRA’s life sciences litigation support services are grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe. We provide clients with the industry and analytical expertise needed to solve our clients’ most complex issues.
Engagements
- 01Successful defense of Amgen-Horizon mergerCRA’s Life Sciences consultants provided economic expert assistance to Amgen in defending against a FTC challenge to its acquisition of Horizon Therapeutics....View engagement
- 02CRA Calculates State Medicaid Damages for Anticompetitive HarmOn behalf of a party to a reverse payment settlement, CRA’s life sciences consultants were asked to calculate damages to a state Medicaid program. The CRA...View engagement
- 03FTC reverses Administrative Law Judge on Illumina/GrailOn April 3, the Federal Trade Commission (FTC) reversed the decision of an Administrative Law Judge by finding that Illumina’s $7.1 billion acquisition of...View engagement
Meet our team
![Gregory Bell | Expert Witness | Charles River Associates]()
Gregory K. BellGroup Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com![Peter Rankin Life Sciences Litigation Charles River Associates]()
![Andrew Tepperman | Life Sciences Litigation | Charles River Associates]()
![]()
![Archan Ruparel | Economist Expert Life Sciences | Charles River Associates]()
Recent events
2025 Antitrust Spring Meeting
Several CRA economists will be speaking at the conference. Wednesday, April 2 at 10:45am: Renée Duplantis is a moderator on “Can antitrust fix the wage gap?”...
Proving But-for Entry Dates in Pharmaceutical Antitrust Litigation
A question arises in most pharmaceutical antitrust cases: when would generic entry have occurred absent the accused conduct? In this program, a panel of...